-
August 2, 2021
R&D Pipeline as of August 2021 -
August 2, 2021
The First Quarter of FY2021 (April 2021 - June 2021) -
May 11, 2021
Annual of FY2020 (April 2020 - March 2021) -
February 1, 2021
The Third Quarter of FY2020 (April 2020- December 2020) -
November 13, 2020
Annual Report 2020
-
September 27, 2021
Marketing Authorization Approval in Japan for TAVNEOS® Capsules 10mg, a selective Complement C5a Receptor Antagonist -
September 15, 2021
New Drug Application submitted to U.S. FDA for Linzagolix for the treatment of uterine fibroids -
September 2, 2021
Licensing Agreement for GnRH Antagonist Linzagolix with Bio Genuine in China -
August 19, 2021
Launch of UPASITA® IV Injection Syringe for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients -
August 5, 2021
Sub-licensing Agreement for Spleen Tyrosine Kinase Inhibitor Fostamatinib with Inmagene Biopharmaceuticals
